Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.42 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20810670 | 0.85 | L3MBTL1 (0.44) | L3MBTL1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29954898 | 0.82 | TRIM24 (0.46) | L3MBTL1TRIM24TRIM33CYP1A2CYP3A4 | |
| SCHEMBL306384 | 0.81 | METAP1 (0.44) | L3MBTL1ALDH1A1TRIM24TRIM33KDM4E | |
| SCHEMBL7351040 | 0.80 | ALDH1A1 (0.41) | L3MBTL1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL7351042 | 0.80 | ALDH1A1 (0.41) | L3MBTL1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3713256 | 0.80 | TRIM24 (0.47) | L3MBTL1ALDH1A1TRIM24TRIM33CYP1A2 | |
| SCHEMBL2556765 | 0.79 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2601270 | 0.79 | NPC1 (0.52) | L3MBTL1ALDH1A1KDM4EPOLBNPC1 | |
| SCHEMBL2494002 | 0.79 | RAB9A (0.59) | L3MBTL1ALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8613491 | 0.78 | L3MBTL1 (0.53) | L3MBTL1ALDH1A1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245132-B1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC NO 41424 (GB) | 2017-10-18 | — | — | EP | claimed |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | TERREMOTO BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2025081045-A9 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| US-20250163079-A1 | KRAS INHIBITORS | INCYTE CORPORATION | 2025-05-22 | — | — | US | disclosed |
| WO-2025096738-A1 | KRAS INHIBITORS | INCYTE CORPORATION (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025081045-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-10968198-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | YALE UNIVERSITY (US) | 2021-04-06 | — | — | US | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20040038963-A1 | Alpha v integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2004-02-26 | — | — | US | disclosed |
| EP-1315501-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2003-04-10 | — | — | US | disclosed |
| US-6410526-B1 | BONE DISORDERS; RESTENOSIS; VISION DISORDERS; ANTICHOLESTEROL AGENTS; ANTICANCER, ANTITUMOR AGENTS | MERCK & CO., INC. | 2002-06-25 | — | — | US | disclosed |
| US-6344449-B1 | HEADACHE AND MORPHINE DEPENDENCE | DR. KARL THOMAE GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
| WO-2002007730-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2001-11-01 | — | — | US | disclosed |
| WO-1991006300-A1 | NAPHTHERIDINONE- AND PYRIDOOXAZINONE-PYRIDONE COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING SAME, AND THEIR USES | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-05-16 | — | — | WO | disclosed |
| US-4906629-A | Pyridazinone and pyrazolone compounds, cardiotonic compositions including same, and their uses | RORER PHARMACEUTICAL CORPORATION (US) | 1990-03-06 | — | — | US | disclosed |
| US-4866074-A | Naphtheridinone- and pyridooxazinone-pyridone compounds, cardiotonic compositions including same, and their uses | RORER PHARMACEUTICAL CORPORATION (US) | 1989-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | L3MBTL1 1743/4885ALDH1A1 2424/4885TRIM24 612/4885 |
| US-10968198-B2 | Biaryltriazole inhibitors of macrophage migration inhibitory factor | MIF, MMP12, CSF1R | L3MBTL1 892/4885ALDH1A1 3264/4885TRIM24 288/4885 |
| US-20040038963-A1 | Alpha v integrin receptor antagonists | ITGAV, ADGRE5, ITGB3 | L3MBTL1 1603/4885ALDH1A1 1039/4885TRIM24 2240/4885 |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | AKT1, AKT2, AKT3 | L3MBTL1 2110/4885ALDH1A1 3594/4885TRIM24 3414/4885 |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | SLC1A5, NEFM, SRMS | L3MBTL1 3426/4885ALDH1A1 1704/4885TRIM24 2194/4885 |
| US-20250163079-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | L3MBTL1 2591/4885ALDH1A1 2350/4885TRIM24 2826/4885 |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT2, AKT3 | L3MBTL1 2270/4885ALDH1A1 3008/4885TRIM24 2982/4885 |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | L3MBTL1 3323/4885ALDH1A1 2196/4885TRIM24 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.